Ulotaront

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities

Retrieved on: 
Monday, July 10, 2023
PIM1, Ruxolitinib, Drug development, Ulotaront, Schizophrenia, Sumitomo Pharma, Research, SMPA, Science, Regenerative medicine, Acute myeloid leukemia, AML, DSM-IV codes, MLL, Patient, Investment, Growth, Health, Psychiatry, Neurology, Urology, Data Analytics Library, Pharmaceutical industry

The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies.

Key Points: 
  • The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies.
  • "We are pleased to have successfully completed the combination of Sumitomo Pharma's U.S. subsidiaries to form SMPA," said Hiroshi Nomura, Representative Director, President and Chief Executive Officer of Sumitomo Pharma.
  • "As a Sumitomo Pharma Group growth engine, SMPA will focus on maximizing the value of the three key products early, namely, ORGOVYX®, MYFEMBREE®, and GEMTESA®.
  • We invite you to learn about SMPA's full leadership team and capabilities on our new website: https://www.us.sumitomo-pharma.com .

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Retrieved on: 
Wednesday, April 26, 2023
Mental Health, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GAD, Commercialization, Senior, Sunovion, Ulotaront, Week, Schizophrenia, Anxiety, TAAR1, Multimedia, Appetite, Trial of the century, Sleep, Hamilton Anxiety Rating Scale, Anxiety disorder, DSM-IV codes, MDD, Patient, Mental health, Safety, Pharmaceutical industry, Nursing

Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD).
  • In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder (MDD).
  • “Preliminary data from preclinical and clinical studies of ulotaront suggest an anxiety-reducing effect, which we aim to understand further in patients with GAD.
  • The primary endpoint is reduced anxiety symptoms, as measured by a change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score, compared to placebo at Week 8.

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

Retrieved on: 
Thursday, April 6, 2023
Technology, Research, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Science, Artificial Intelligence, Partnership, Depression, Sunovion, Schizophrenia, Biomarker, DSM-IV codes, CNS, Patient, Machine learning, Psychology, EEG, Ecube Labs, Ulotaront, Pharmaceutical industry, Medical device

PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform to support phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.

Key Points: 
  • PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform to support phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
  • “The eCube platform joins PsychoGenics’ innovative class of AI-enabled phenotypic platforms, including SmartCube, which has helped advance numerous compounds to clinical trials, including Ulotaront.
  • Discovered in partnership with Sunovion, Ulotaront is now in Phase 3 for schizophrenia, as well as depression and generalized anxiety disorder,” said Emer Leahy, Ph.D., CEO, PsychoGenics.
  • “This powerful platform can confirm the therapeutic predictions from our behavior-based platforms, identify neuronal circuitry and provide translational biomarkers to support clinical development.”